Dermatology

A possible association between hidradenitis suppurativa (HS) with chronic kidney disease (CKD) suggests that patients with HS who present signs of CKD should be assessed by a nephrologist, suggests a study.

Some populations face longer diagnostic delays for hidradenitis suppurativa (HS), but medical education can help improve knowledge of common dermatologic diseases and reduce delays in diagnosis, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.

Women with hidradenitis suppurativa (HS) reported higher fertility rates compared to the general population, and most said HS symptoms did not change with fertility treatments.

Some of the many barriers patients with hidradenitis suppurativa (HS) face include accessing knowledgeable providers, insurance coverage of treatment, and the way the health care system is set up, said Haley Naik, MD, FAAD, associate professor of dermatology, University of California, San Francisco, School of Medicine.

The personalizing actinic keratosis treatment (PAKT) tool may have the ability to strengthen patient-centric management of actinic keratoses (AK) in clinical practice, account for patient goals, and form reasonable treatment and care outcomes.

Hidradenitis suppurativa (HS) is associated with multiple comorbidities and is underreported in developing countries, necessitating further research.

The American Skin Association estimated that 50 million Americans are exposed to urushiol yearly, the most common contact allergen in the United States.

Some of the results with biologics and Janus kinase (JAK) inhibitors for atopic dermatitis have been better in practice compared with clinical trials, said Emma Guttman-Yassky, MD, PhD, FAAD, of the Icahn School of Medicine at Mount Sinai.

Patients with the chronic skin condition hidradenitis suppurativa were less likely to be hospitalized with COVID-19 vs a control group.

More attention should be paid to prevent acne scarring and address the psychosocial consequences associated with it, authors argue.

Although previous research has explored and documented the prevalence of stigma facing people with chronic skin conditions, less is known about how patients respond to such stigma.

This retrospective study showed that anti–interleukin-17 drug secukinumab yielded favorable results in a small group of patients with severe hidradenitis suppurativa (HS).

Telemedicine is effective to diagnose and treat various dermatologic conditions in the pediatric population.

Matthew Mansh, MD, FAAD, discusses inequities faced by transgender and gender-diverse patient populations.

The findings are based on survey responses and focus group transcripts reflecting the experiences of nine patients.

Past research shows no meaningfully increased risk of venous thromboembolism (VTE) in patients with more common chronic inflammatory skin diseases.

The incidence rate of melanoma in situ (MIS) has sharply risen since 1975.

Findings are based on a retrospective, multicenter study carried out in Spain.

Lower socioeconomic status (SES) was not linked with hidradenitis suppurativa (HS) in minors, but was associated with obesity and tobacco use in this age group.

The approval makes the drug Europe’s first and only interleukin (IL)-17A inhibitor approved for the condition.

With surveys demonstrating that care disparities in atopic dermatitis (AD) may exist among pediatric patients with the chronic skin condition, investigators set out to determine AD’s prevalence by sociodemographic subgroup.

Although acne and rosacea treatment are widely covered, treatment for other types of skin conditions are not covered at all, a new report shows.

Melinda Gooderham, MD, MSc, FRCPC, Peterborough Regional Health Centre in Ontario, Canada, discusses recent trials and studies that have been conducted on emerging therapies for patients with atopic dermatitis.

The study, using an adaption of the World Health Organization framework for adherence, characterized strategies built into the design, conduct, and reporting of melanoma trials, offering insights into potential improvements for skin self-examination in research.

Common treatments for acne are known to be unsafe for pregnant women, but alternative treatments exist that are safe for use; however, actual treatment patterns within this patient population are unclear.